SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by GlaxoSmithKline plc for the month of June 2020, dated June 1, 2020. The filing serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the Company's total voting rights and capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document focuses solely on the static capital structure as of May 31, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under UK disclosure rules.
Key Facts for Investor Verification
- Issued Share Capital: As of May 31, 2020, the Company had 5,384,879,604 Ordinary Shares of 25 pence each.
- Treasury Shares: 367,705,950 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 5,017,173,654.
- Usage: This figure is the official denominator for shareholders to determine if they must notify the Company of their interest or changes thereto.